Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F10%3A10215584" target="_blank" >RIV/61989592:15110/10:10215584 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma

Popis výsledku v původním jazyce

The aim of this study was to develop, validate and compare FIA- and UHPLC-MS/MS methods for the determination of imatinib (IM) in plasma from patients with chronic myeloid leukemia. The plasma was deproteinated by methanol containing d8-IM. The separation was achieved on a 1.7 mým C18 column with a linear gradient (4 mM NH4COOH and AcCN; pH 3.2). FIA was performed at flow rate of 0.03 mL/min (0.1% formic acid in methanol). MRM mode on the tandem mass spectrometer in positive ESI were used for detection.The total analysis times were 3.2 (LC) and 0.75 min (FIA). Both methods were successfully validated and applied to the patients samples. The limits of quantification were 4.1 and 30.8 ng/mL; imprecisions were less than 5.7% and recovery ranged between 93 and 105%, for the LC and FIA, respectively. The methods correlated with a mean difference of 1.46 ng/mL (SD 28.95 ng/mL). Both methods are suitable for the therapeutic drug monitoring of IM in plasma and can be used in routine clinical

Název v anglickém jazyce

Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma

Popis výsledku anglicky

The aim of this study was to develop, validate and compare FIA- and UHPLC-MS/MS methods for the determination of imatinib (IM) in plasma from patients with chronic myeloid leukemia. The plasma was deproteinated by methanol containing d8-IM. The separation was achieved on a 1.7 mým C18 column with a linear gradient (4 mM NH4COOH and AcCN; pH 3.2). FIA was performed at flow rate of 0.03 mL/min (0.1% formic acid in methanol). MRM mode on the tandem mass spectrometer in positive ESI were used for detection.The total analysis times were 3.2 (LC) and 0.75 min (FIA). Both methods were successfully validated and applied to the patients samples. The limits of quantification were 4.1 and 30.8 ng/mL; imprecisions were less than 5.7% and recovery ranged between 93 and 105%, for the LC and FIA, respectively. The methods correlated with a mean difference of 1.46 ng/mL (SD 28.95 ng/mL). Both methods are suitable for the therapeutic drug monitoring of IM in plasma and can be used in routine clinical

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CB - Analytická chemie, separace

OECD FORD obor

—

Projekt

<a href="/cs/project/NS9627" target="_blank" >NS9627: Význam buněčných transportních mechanismů pro účinnost léčby imatinib mesylátem u nemocných s chronickou myeloidní leukemií</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinica Chimica Acta

ISSN

0009-8981

e-ISSN

—

Svazek periodika

411

Číslo periodika v rámci svazku

23-24

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

000283916600018

EID výsledku v databázi Scopus

—